Clinical Trial Update: Cx611-0204 SEPCELL Study [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical trial (SEPCELL Study) evaluating Cx611-0204 for bacterial pneumonia, with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Pneumonia

Drugs mentioned

• Cx611-0204

Snippet

Sponsor: Tigenix S.A.U. | Conditions: Bacterial Pneumonia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-04-06